Blueprint Medicines Corporation (BPMC)
NASDAQ: BPMC · Real-Time Price · USD
127.96
-0.25 (-0.19%)
At close: Jun 13, 2025, 4:00 PM
128.06
+0.10 (0.08%)
After-hours: Jun 13, 2025, 4:23 PM EDT
Blueprint Medicines Stock Forecast
Stock Price Forecast
According to 17 professional analysts, the 12-month price target for Blueprint Medicines stock ranges from a low of $105 to a high of $151. The average analyst price target of $129.12 forecasts a 0.91% increase in the stock price over the next year.
Price Target: $129.12 (+0.91%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Blueprint Medicines stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 6 | 7 | 6 | 6 | 4 |
| Buy | 7 | 7 | 8 | 8 | 8 | 3 |
| Hold | 5 | 5 | 6 | 6 | 6 | 13 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 1 | 1 | 1 | 1 | 1 | 0 |
| Total | 19 | 19 | 22 | 21 | 21 | 20 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Morgan Stanley | Morgan Stanley | Hold Maintains $102 → $129 | Hold | Maintains | $102 → $129 | +0.81% | Jun 5, 2025 |
| UBS | UBS | Hold Maintains $88 → $129 | Hold | Maintains | $88 → $129 | +0.81% | Jun 5, 2025 |
| Citigroup | Citigroup | Strong Sell → Hold Upgrades $83 → $129 | Strong Sell → Hold | Upgrades | $83 → $129 | +0.81% | Jun 4, 2025 |
| JMP Securities | JMP Securities | Buy → Hold Downgrades n/a | Buy → Hold | Downgrades | n/a | n/a | Jun 3, 2025 |
| Stephens & Co. | Stephens & Co. | Buy → Hold Downgrades $150 → $135 | Buy → Hold | Downgrades | $150 → $135 | +5.50% | Jun 3, 2025 |
Financial Forecast
Revenue This Year
734.46M
from 508.82M
Increased by 44.34%
Revenue Next Year
973.58M
from 734.46M
Increased by 32.56%
EPS This Year
-0.96
from -1.07
EPS Next Year
1.04
from -0.96
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 811.7M | 1.1B | 1.4B | ||
| Avg | 734.5M | 973.6M | 1.2B | ||
| Low | 692.4M | 841.8M | 904.4M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 59.5% | 45.1% | 48.0% | ||
| Avg | 44.3% | 32.6% | 24.4% | ||
| Low | 36.1% | 14.6% | -7.1% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 1.24 | 3.22 | 7.52 | ||
| Avg | -0.96 | 1.04 | 4.42 | ||
| Low | -2.05 | -1.92 | 2.25 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | 624.5% | ||
| Avg | - | - | 326.0% | ||
| Low | - | - | 117.2% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.